Two key events that will shape the future of medicines regulation in Europe are taking place on Thursday. The European Parliament, which is holding confirmation hearings this week on the incoming team of European Commissioners, will scrutinize a controversial proposal from Jean Claude Juncker, the president of the new commission, to transfer oversight of the EMA back to the EU's Directorate General (DG) for Enterprise, which now has the new – and unwieldy – name of DG Internal Market, Industry, Entrepreneurship and SMEs.